BioMed Partners has invested in Tolremo therapeutics as part of USD9.3 million Series A financing round.
Tolremo therapeutics was founded in March 2017 as a Spin-off from ETH Zürich. Tolremo’s proprietary platform has the potential to change cancer therapy by targeting resistance-causing molecular mechanisms up-front, thereby addressing drug resistance proactively before it develops.
Tolremo therapeutics has also further strengthened its Board of Directors with the oncology, medical and industry experts Dr. Erich Greiner, Prof. em. Thomas Cerny, and Dr Andreas Wallnöfer. Dr Wallnöfer, General Partner BioMedPartners will represent BioMed on the board.